[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"burn-wounds\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:burn-wounds":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,43,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100633693","phase-1-humscs-combined-with-col-i-to-third-degree-burn-wound-100633693",false,"NCT07530003","HUMSCs Combined With Col I to Third-Degree Burn Wound","A Single-Center, Randomized, Double-Blind, Placebo-Controlled Exploratory Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Combined With Bovine Type I Collagen for Promoting Third-Degree Burn Wound Repair","Inclusion Criteria:\n\n* Aged 18-65 years, gender unrestricted\n* Confirmed third-degree burns, wound area 1%-5% TBSA\n* Admission within 72 hours after burn injury\n* Voluntarily signed informed consent\n* Able to cooperate and complete follow-up\n\nExclusion Criteria:\n\n* Pregnant or lactating females\n* Severe immunodeficiency or autoimmune disease\n* History of malignant tumor, or coagulation dysfunction\n* Severe cardiac, hepatic, or renal insufficiency\n* Hypersensitivity to collagen or stem cell components\n* Uncontrollable severe wound infection\n* Participation in other clinical studies within the past 3 months\n* Inability to comply with follow-up","ALL","18 Years","65 Years",{"count":20,"type":21},108,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","To evaluate the safety and tolerability of human umbilical cord mesenchymal stem cells combined with bovine type I collagen in the treatment of third-degree burn wounds.",[28,29],"Burn Wounds","Third-Degree Burn Wounds","RECRUITING","2026-04-28",{"date":33,"type":34},"2026-05-04","ACTUAL",{"date":36,"type":21},"2026-04-06",{"date":38,"type":21},"2028-12-31",{"name":40,"class":41},"The First Affiliated Hospital of Xinxiang Medical College","OTHER",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":50,"sex":16,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100592397","the-effect-of-hologram-application-on-pain-anxiety-and-fear-levels-in-children-during-burn-dressing-100592397","NCT06992895","The Effect of Hologram Application on Pain, Anxiety, and Fear Levels in Children During Burn Dressing","Effect of Hologram Application on Pain, Anxiety and Fear Levels During Burn Dressing in Children: A Randomized Controlled Trial","Inclusion Criteria:\n\n* The subject has indicated their willingness to participate in the study. Physical and mental health.\n* The age range of the subjects included in this study was from 3 to 12 years of age.\n* The subject had never previously engaged in the practice of dressing a burn.\n* The presence of only second degree burns\n* Burn percentage is under 10%\n\nExclusion Criteria:\n\n* The subject is unwilling or unable to provide informed consent or assent (if applicable).\n* The subject has a history of significant physical or mental health disorders that may interfere with participation in the study.\n* The subject is younger than 3 years old or older than 12 years old.\n* The subject has previously engaged in the practice of burn dressing or similar procedures.\n* The presence of burns other than second-degree burns (e.g., first-degree or third-degree burns).\n* The percentage of burn area is greater than 10%.",true,"3 Years","12 Years",{"count":54,"type":21},70,[56],"NA","The process of dressing burn injuries has been shown to cause both physical and psychological difficulties. In children, this process is particularly associated with intense pain and anxiety. Consequently, in addition to pharmacological interventions, non-pharmacological methods such as distraction are employed. In recent years, the utilization of holograms as a method of alleviating pain has emerged as a novel approach. The employment of these visual illusions has been demonstrated to effectively distract children, thereby providing a means of reducing discomfort. The objective of this thesis is to evaluate the effects of hologram application on pain, anxiety, fear, and vital signs during burn dressing in children.",[28,59],"Burn",[61,62,63,64,65],"Holography","Burns","Pain","Anxiety","Fear","2026-04-07",{"date":68,"type":34},"2026-04-13",{"date":70,"type":34},"2025-10-15",{"date":72,"type":21},"2026-06-20",{"name":74,"class":41},"Ataturk University",2,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":87,"conditions":88,"keywords":96,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":4},"100610154","phase-3-efficacy-of-carbonlife-amniotic-tissue-product-in-the-treatment-of-chronic-wounds-100610154","NCT07223892","Efficacy of Carbonlife Amniotic Tissue Product in the Treatment of Chronic Wounds","A Prospective Controlled Trial Evaluating the Efficacy of Carbonlife Amniotic Tissue Product in the Treatment of Chronic Wounds: A Stratified Analysis by Wound Etiology and Care Setting","Inclusion Criteria:\n\n* Facilities and centers with the capacity to follow strict treatment and care guidelines for patients.\n* Adults aged 18 years or older.\n* Presence of a chronic wound (defined as a wound that has not shown significant improvement in 4 weeks) of any of the following etiologies: Diabetic foot ulcers, Venous leg ulcers, Arterial ulcers, Pressure ulcers, Burns, Trauma, Surgical\n* Wound size greater than 1 cm²\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Presence of active osteomyelitis\n* Untreated malignancy in the wound area\n* Known allergy to components of ATPs\n* Pregnant or breastfeeding women\n* Patients receiving immunosuppressive therapy\n* Patients with a life expectancy of less than 12 weeks",{"count":84,"type":21},600,[86],"PHASE3","Chronic wounds constitute a significant global health burden, affecting millions of individuals and contributing to increased morbidity, diminished quality of life, and rising healthcare costs. These wounds are characterized by delayed healing and are often associated with complex etiologies and prolonged treatment courses. This study aims to evaluate the clinical efficacy and cost-effectiveness of Carbonlife amniotic tissue products (ATPs) compared to standard wound care in the management of chronic wounds. A prospective, controlled clinical trial will be conducted across diverse care settings and patient populations with varying wound etiologies. Participants will be stratified by wound type and treatment environment to enable subgroup analyses. The primary endpoint will assess wound healing outcomes, while secondary endpoints will include quality-of-life measures and healthcare resource utilization. The study is designed to generate high-quality evidence regarding the therapeutic value of ATPs in chronic wound management. Stratified analyses will provide insights into the differential effectiveness of ATPs across clinical contexts. Findings are anticipated to have implications for clinical practice guidelines and healthcare policy, with the goal of improving patient outcomes and optimizing resource allocation in wound care.",[89,90,91,92,93,28,94,95],"Chronic Wounds","Venous Leg Ulcers (VLUs)","Diabetic Foot Ulcers (DFUs)","Arterial Ulcers","Pressure Ulcers","Trauma Wounds","Surgical Wounds",[97],"chronic wounds","NOT_YET_RECRUITING","2025-11-04",{"date":101,"type":34},"2025-11-06",{"date":103,"type":21},"2026-01-01",{"date":105,"type":21},"2028-03",{"name":107,"class":108},"Bardia Anvar","INDUSTRY"]